Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs

• Published in: Chemical papers Vol. 77; no. 8; pp. 4085 - 4106
• Main Authors: Chandra, Girish, Singh, Durg Vijay, Mahato, Gopal Kumar, Patel, Samridhi
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2023; Springer Nature B.V
• Subjects: Biochemistry; Biotechnology; Chemical properties; Chemical synthesis; Chemistry; Chemistry and Materials Science; Chemistry/Food Science; COVID-19; Disease control; Drugs; FDA approval; Fluorination; Fluorine; Industrial Chemistry/Chemical Engineering; Materials Science; Medicinal Chemistry; Positron emission; Review; Drug design and development; FDA; Fluorinated drugs; Synthesis; Covid-19; PET
• ISSN: 0366-6352; 2585-7290; 1336-9075
• DOI: 10.1007/s11696-023-02804-5

During the last twenty years, organic fluorination chemistry established itself as an important tool to get a biologically active compound. This belief can be supported by the fact that every year, we are getting fluorinated drugs in the market in extremely significant numbers. Last year, also ten fluorinated drugs have been approved by FDA and during the COVID-19 pandemic, fluorinated drugs played a very crucial role to control the disease and saved many lives. In this review, we surveyed all ten fluorinated drugs approved by FDA in 2021 and all fluorinated drugs which were directly-indirectly used during the COVID-19 period, and emphasis has been given particularly to their synthesis, medicinal chemistry, and development process. Out of ten approved drugs, one drug pylarify, a radioactive diagnostic agent for cancer was approved for use in positron emission tomography imaging. Also, very briefly outlined the significance of fluorinated drugs through their physical, and chemical properties and their effect on drug development. Graphical abstract